🧬 AC-262,536 Research Overview

Experimental Selective Androgen-Receptor Modulator

AC-262,536 is an experimental, nonsteroidal selective androgen-receptor modulator, commonly abbreviated as a SARM.

It was developed to investigate whether androgen-receptor activity could be directed more strongly toward anabolic tissues while producing weaker effects in androgen-sensitive reproductive tissues than testosterone.

The primary published evidence consists of cell-based experiments and a short study in castrated male rats. There are no published controlled human trials establishing its safety, effectiveness, pharmacokinetics, or effects on muscle mass.

AC-262,536 is not approved by the FDA for human use.

🔬 How AC-262,536 Is Being Studied

The androgen receptor is involved in the biological effects of testosterone and other androgens. These effects can occur across numerous tissues, including:

• Skeletal muscle

• Bone

• Prostate

• Seminal vesicles

• Pituitary tissue

• Reproductive organs

The objective behind SARM research is to identify compounds that produce different degrees of androgen-receptor activity across different tissues.

However, “selective” does not mean that a compound affects only muscle. Tissue selectivity is relative, dependent on the experimental model, and may change according to exposure.

Research interest: androgen-receptor binding, partial agonism, anabolic signaling, reproductive-tissue effects, and tissue-selective pharmacology.

🧪 Cell-Based Findings

In laboratory assays, AC-262,536 was identified as an androgen-receptor ligand with partial agonist activity relative to testosterone.

A partial agonist activates a receptor but may produce a smaller maximum response than a full agonist under the same experimental conditions.

The cell-based findings supported further investigation of AC-262,536, but they do not establish:

• Muscle growth in humans

• Increased human strength

• Reduced body fat

• Minimal hormonal suppression

• Liver safety

• An absence of androgenic effects

Cell-based receptor activity cannot determine the complete effect of a compound within a living human body.

🐀 What the Animal Study Found

A 2008 study published in the Journal of Steroid Biochemistry and Molecular Biology evaluated AC-262,536 in castrated male rats over two weeks.

Researchers reported that AC-262,536:

• Increased the weight of the levator ani muscle

• Suppressed elevated luteinizing-hormone levels

• Produced weaker effects on prostate weight than testosterone

• Produced weaker effects on seminal-vesicle weight than testosterone

These findings suggested a degree of tissue selectivity in that particular animal model.

The experiment did not measure bodybuilding outcomes in people. It also did not establish that AC-262,536 safely increases human skeletal-muscle mass or avoids effects on the endocrine and reproductive systems.

⚠️ What “Anabolic” Meant in the Study

The principal anabolic measurement was growth of the rat levator ani muscle. This is a traditional androgen-sensitive tissue assay used during the early evaluation of anabolic compounds.

An increase in levator ani weight in castrated rats is not equivalent to scientifically proven muscle gains in humans.

The study did not evaluate:

• Resistance-trained participants

• Human lean-body mass

• Human strength or athletic performance

• Fat loss or body recomposition

• Human testosterone production

• Human liver enzymes

• Hair loss

• Gynecomastia

• Long-term cardiovascular outcomes

• Cancer incidence

The cited study therefore cannot support claims that AC-262,536 is a proven, safe, or low-risk muscle-building compound.

🧬 Endocrine Signaling

The rat study found that AC-262,536 suppressed elevated luteinizing-hormone levels in castrated animals. That observation is directly inconsistent with describing the compound as definitively “non-suppressive.”

The endocrine response of intact humans has not been established. There are no controlled human data defining its effects on:

• Total or free testosterone

• Luteinizing hormone

• Follicle-stimulating hormone

• Estradiol

• Sex hormone-binding globulin

• Fertility

• Recovery following exposure

Descriptions such as “minimal suppression,” “easy recovery,” or “ideal for bridging” are unsupported by controlled evidence.

⚠️ Prostate and Androgenic Effects

AC-262,536 produced weaker changes in rat prostate and seminal-vesicle weights than testosterone under the studied conditions.

This does not establish that it has no prostate effects. It also does not prove a reduced risk of prostate cancer, hair loss, acne, or other androgen-related outcomes in humans.

Lower activity in two rat tissues over two weeks cannot establish long-term human safety.

⚠️ Liver and Cardiovascular Safety

No controlled human trials have established that AC-262,536 is liver-safe.

The available animal study also does not adequately establish its effects on:

• Liver enzymes

• Liver injury

• HDL or LDL cholesterol

• Blood pressure

• Cardiac structure

• Blood-cell production

• Blood-clotting risk

Claims of low liver toxicity or overall safety cannot be supported without appropriate toxicology and controlled clinical research.

⚠️ What the Evidence Does Not Establish

Current evidence does not establish that AC-262,536:

• Produces muscle gains in humans

• Increases human strength

• Reduces body fat

• Preserves muscle during a calorie deficit

• Produces less water retention

• Causes minimal testosterone suppression

• Avoids hair loss or acne

• Prevents estrogen-related effects

• Has low liver toxicity

• Reduces prostate or cancer risk

• Requires easier hormonal recovery than other SARMs

• Is safe for short- or long-term human use

No scientifically validated human exposure range exists, and animal-study quantities should not be converted into instructions for personal use.

⚠️ Research Limitations

• The principal published study used castrated male rats.

• The animal experiment lasted only two weeks.

• Human pharmacokinetics have not been established.

• Controlled human safety and efficacy data are absent.

• Long-term reproductive, hepatic, cardiovascular, and cancer-related risks are unknown.

• “Selective” does not mean muscle-only or side-effect-free.

• Product identity, purity, strength, and stability may vary among research materials.

• The original study does not validate any commercial capsule product.

⭐ Evidence-Based Verdict

AC-262,536 demonstrated partial androgen-receptor agonism in cell assays and anabolic activity in a short castrated-rat study. It produced greater effects on an androgen-sensitive muscle than on prostate and seminal-vesicle weights under the tested conditions.

That makes AC-262,536 scientifically interesting as an early-stage tissue-selective androgen-receptor compound. It does not make it a clinically proven muscle-building agent with minimal side effects.

The most accurate conclusion is that AC-262,536 has limited preclinical evidence of anabolic and tissue-selective activity, no established human benefits, and an uncharacterized human safety profile.

Learn more about AC-262,536

Affiliate disclosure: The link above is a referral link. I may receive a commission if it is used, at no additional cost to the purchaser.

For laboratory-research purposes only. Not for human or veterinary use.

This material is provided solely for general educational discussion of preclinical research. It is not medical advice, does not provide dosing, cycle, stacking, or recovery instructions, does not recommend personal use or self-experimentation, and does not claim that AC-262,536 can diagnose, treat, cure, or prevent any disease.